Development and psychometric properties of the HPV Impact Profile (HIP) to assess the psychosocial burden of HPV

References

• Ferlay J, Bray F, Pisani P, et al. GLOBOCAN 2002: cancer incidence, mortality and prevalence worldwide. IARC Cancer Base No 5 Version 2 0 IARC Press Lyon, France, 2002. Available at: http://www-dep.iarc.fr/globocan/database.htm [Last accessed 15 October 2008]
   Google Scholar
• Sirovich BE, Welch HG. The frequency of Pap smear screening in the United States. J Gen Intern Med 2004;19:243-50
   PubMed Web of Science ®Google Scholar
• Muñoz N, Castellsague X, de Gonzalez AB, et al. HPV in the etiology of human cancer. Vaccine 2006;24:S1-10
   PubMed Web of Science ®Google Scholar
• Parkin DM, Bray F. Chapter 2: The burden of HPV-related cancers. Vaccine 2006;24:S11-25
   Web of Science ®Google Scholar
• Lacey CJ. Therapy for genital human papillomavirus-related disease. J Clin Virol 2005;32:S82-90
   PubMed Web of Science ®Google Scholar
• Franco EL, Monsonego J. Epidemiology of cervical human papillomavirus infection. In: Franco EL, ed. New Developments in Cervical Screening and Prevention. Oxford, UK: Blackwell Science, 1997:14-22
   Google Scholar
• Tortolero-Luna G. Epidemiology of genital human papillomavirus. Hematol Oncol Clin North Am 1999;13:245-57
   PubMed Web of Science ®Google Scholar
• Persson G, Dahlf LG, Krantz I. Physical and psychological effects of anogenital warts on female patients. Sex Transm Dis 1993;20:10-13
   PubMed Web of Science ®Google Scholar
• Lacey CJ, Lowndes CM, Shah KV. Chapter 4: Burden and management of non-cancerous HPV-related conditions: HPV-6/11 disease. Vaccine 2006;24:S35-41
   Web of Science ®Google Scholar
• GlaxoSmithKline Biologicals. CERVARIX® product information. GSK Australia, 2008. Available at: http://www.gsk.com.au/resources.ashx/vaccineproductschilddataproinfo/94/FileName/7A14FBAEA16635A2DD7A68ED78E8FDDC/PI_Cervarix.pdf. [Last accessed 15 October 2008]
   Google Scholar
• Fleurence RL, Dixon JM, Milanova TF, et al. Review of the economic and quality-of-life burden of cervical human papillomavirus disease. Am J Obstet Gynecol 2007;196:206-12
   PubMed Web of Science ®Google Scholar
• Rogstad KE. The psychological impact of abnormal cytology and colposcopy. BJOG 2002;109:364-8
   PubMed Web of Science ®Google Scholar
• Maggino T, Casadei D, Panontin E, et al. Impact of an HPV diagnosis on the quality of life in young women. Gynecol Oncol 2007;107:S175-9
   PubMed Web of Science ®Google Scholar
• Kahn JA, Chiou V, Allen JD, et al. Beliefs about Papanicolaou smears and compliance with Papanicolaou smear follow-up in adolescents. Arch Pediatr Adolesc Med 1999;153:1046-54
   PubMed Web of Science ®Google Scholar
• Cullen J, Schwartz MD, Lawrence WF, et al. Short-term impact of cancer prevention and screening activities on quality of life. J Clin Oncol 2004;22:943-52
   PubMed Web of Science ®Google Scholar
• Gray NM, Sharp L, Cotton SC, et al. Psychological effects of a low-grade abnormal cervical smear test result: anxiety and associated factors. Br J Cancer 2006;94:1253-62
   PubMed Web of Science ®Google Scholar
• French DP, Maissi E, Marteau TM. Psychological costs of inadequate cervical smear test results. Br J Cancer 2004;91:1887-92
   PubMed Web of Science ®Google Scholar
• Doherty IE, Richardson PH, Wolfe CD, et al. The assessment of the psychological effects of an abnormal cervical smear result and subsequent medical procedures. In Baum A, et al., eds. Cambridge Handbook of Psychology, Health and Medicine, 12th edn. Cambridge, UK: Cambridge University Press, 1991:319-24
   Google Scholar
• Wardle J, Pernet A, Stephens D. Psychological consequences of positive results in cervical cancer screening. Psychol Health 1995;10:185-94
   Web of Science ®Google Scholar
• Bennetts A, Irwig L, Oldenburg B, et al. Peaps-Q - a questionnaire to measure the psychosocial effects of having an abnormal pap smear. J Clin Epidemiol 1995;48:1235-43
   PubMed Web of Science ®Google Scholar
• Shinn E, Basen-Engquist K, Le T, et al. Distress after an abnormal Pap smear result: scale development and psychometric validation. Prev Med 2004;39:404-12
   PubMed Web of Science ®Google Scholar
• Gray NM, Sharp L, Cotton SC, et al. Developing a questionnaire to measure the psychosocial impact of an abnormal cervical smear result and its subsequent management: the TOMBOLA (trial of management of borderline and other low-grade abnormal smears) trail. Qual Life Res 2005;14:1553-62
   PubMed Web of Science ®Google Scholar
• Woodhall S, Ramsey T, Cai C, et al. Estimation of the impact of genital warts on health-related quality of life. Sex Transm Infect 2008;84:161-6
   PubMed Web of Science ®Google Scholar
• Vilata JJ, Varela JA, Olmos L, et al. Validation and clinical use of the CECA, a disease-specific quality of life questionnaire for patients with anogenital condylomata acuminata. Acta Derm Venereol 2008;88:257-62
   PubMed Web of Science ®Google Scholar
• Badia X, Colombo JA, Lara N, et al. Combination of qualitative and quantitative methods for developing a new health related quality of life measure for patients with anogenital warts. Health Qual Life Outcomes 2005;3:24
   PubMedGoogle Scholar
• Sheehan DV, Harnett-Sheehan K, Raj BA. The measurement of disability. Int Clin Psychopharmacol 1996;11:89-95
   PubMed Web of Science ®Google Scholar
• Sheehan KH, Sheehan DV. Assessing treatment effects in clinical trials with the discan metric of the Sheehan Disability Scale. Int Clin Psychopharmacol 2008;23:70-83
   PubMed Web of Science ®Google Scholar
• Hobart JC, Riazi A, Lamping DL, et al. Improving the evaluation of therapeutic interventions in multiple sclerosis: development of a patient-based measure of outcome. Health Technol Assess 2004;8:1-48
   Web of Science ®Google Scholar
• Wu AW, Fink NE, Cagney KA, et al. Developing a health-related quality-of-life measure for end-stage renal disease: the CHOICE health experience questionnaire. Am J Kidney Dis 2001;37:11-21
   PubMed Web of Science ®Google Scholar
• Holmes W, Bix B, Shea J. SF-20 score and item distributions in a human immunodeficiency virus-seropositive sample. Med Care 1996;34:562-9
   PubMed Web of Science ®Google Scholar
• Leplege A, Rude N, Ecosse E, et al. Measuring quality of life from the point of view of HIV-positive subjects: the HIV-QL31. Qual Life Res 1997;6:585-94
   PubMed Web of Science ®Google Scholar
• Ware JE, Jr Gandek B. Methods for testing data quality, scaling assumptions, and reliability: the IQOLA project approach, international quality of life assessment. J Clin Epidemiol 1998;51:945-52
   PubMed Web of Science ®Google Scholar
• Cronbach LJ. Coefficient alpha and the internal structure of tests. Psychometrika 1951;16:2917
   Google Scholar
• Snaith RP. The hospital anxiety and depression scale. Health Qual Life Outcomes 2003;1:29
   PubMedGoogle Scholar
• Bjelland I, Dahl AA, Haug TT, et al. The validity of the hospital anxiety and depression scale -- an updated literature review. J Psychosom Res 2002;52:69-77
   PubMed Web of Science ®Google Scholar
• Pirotta M, Stein A, Conway EL, et al. The psychosocial burden of HPV-related disease and screening interventions. Sex Transm Infect 2009; In press.
   Google Scholar
• Pitts M, Clarke T. Human papillomavirus infections and risks of cervical cancer: what do women know?. Health Educ Res 2002;17:706-14
   PubMed Web of Science ®Google Scholar